Johnson & Johnson ’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer

RARITAN, N.J., Dec. 4, 2023– Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD) for the potential future treatment of patients with Bacillus...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials